Here are the DEF 14A proxy statements from FutureTech II Acq CRP A (FTII) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow FTII and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FTII filings page.
FutureTech II Acquisition Corp., a blank check company, is calling an August 13, 2026 virtual special meeting to seek stockholder approval to amend its Charter and extend the deadline to complete an initial business combination by nine months, from August 18, 2026 to May 18, 2027. A related proposal would allow adjournment of the meeting to solicit more proxies if needed.
The extension is intended to provide more time to close the planned Business Combination with Longevity Biomedical Inc., which management aims to complete by December 31, 2026. Public stockholders may elect to redeem their shares now for their pro rata portion of the Trust Account, estimated at approximately $12.84 per share before estimated taxes and $12.63 after, based on $7.082 million in trust as of June 30, 2026.
If the Charter Amendment is not approved and no business combination closes by August 18, 2026, or if no deal closes by the extended date, FutureTech would redeem all public shares and liquidate, leaving warrants worthless. Shares currently trade on the OTC Markets, raising liquidity and penny stock concerns and potentially complicating Nasdaq listing for the post-combination company. Insiders holding approximately 86.4% of outstanding shares intend to vote for both proposals.